Major automakers are making billion-pound strategic shifts away from all-electric focus. This massive industry correction creates fresh opportunities for hybrid and combustion engine suppliers.
As manufacturers adjust their production roadmaps, companies supplying traditional and hybrid components could see increased demand after facing headwinds from aggressive EV pushes.
These handpicked companies operate in critical automotive supply chain segments, positioning them to capitalise on the industry's more balanced approach to powertrain technologies.
Stellantis's £26 billion charge represents a major industry correction, signalling that the all-electric transition is happening more gradually than anticipated. This creates a strategic opportunity to invest in companies that supply parts for hybrid and traditional combustion engines, as automakers pivot towards more diverse powertrain options.
This group focuses on the automotive supply chain, specifically companies that manufacture essential components for hybrid and internal combustion engine vehicles. These firms operate in a critical segment that had faced headwinds from aggressive EV push but now stands to benefit from renewed demand as manufacturers adjust their strategies.
Each company in this collection has been handpicked by professional analysts for their strategic positioning in the powertrain pivot. From engine components to exhaust systems, these businesses are well-positioned to capitalise on the industry's adjusted production roadmaps and the renewed focus on hybrid technology.
Stellantis's $26 billion strategy reset highlights a major industry pivot away from an all-electric focus. This shift creates a potential investment opportunity in companies that supply parts for hybrid and traditional combustion engine vehicles.
This basket's total market capitalisation is $580.60B and is heavily concentrated in a few large-cap constituents that anchor its profile. That concentration tends to produce greater stability but may limit upside from smaller, higher-growth names.
TM: $380.21B
HMC: $56.89B
BWA: $11.17B
+5
Here are a few of the assets in this group. Create an account to unlock the full list.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+58.85%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 58.85 % zulegen.
14 von 15 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Vollständige Analyse lesen
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
